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Large cell neuroendocrine carcinoma (LCNEC) is a relatively new
category of pulmonary neuroendocrine tumor. Although it was first
detected in the lung, LCNEC has since been found in a variety of
extrapulmonary sites. We now describe a patient who was diagnosed
with LCNEC originating from the mediastinum, an extremely rare
disorder. An increased serum concentration of -fetoprotein (AFP)
in the patient was reduced by chemotherapy in association with
tumor shrinkage. Furthermore, the tumor was confirmed immuno-
histochemically to produce AFP. To our knowledge, this is the first
report of a LCNEC that produces AFP.
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Large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine tumor that was first detected in the
lung by Travis et al.1 The prognosis of individuals with
LCNEC has been reported to be poor, with a 5-year survival
rate similar to that for small cell carcinoma.2–4 Although
originally found in the lung, LCNEC has since been described in
a variety of extrapulmonary locations.5–7 Among these locations,
mediastinal LCNEC is extremely rare, with only a few cases
having been reported.8,9 We now report the first case of medi-
astinal LCNEC with -fetoprotein (AFP) production.
CASE REPORT
A previously healthy 35-year-old Japanese man was
found to have an abnormal mass in his right mediastinum on
a chest radiograph during a health checkup. The patient’s
general condition was fair, and symptoms such as chest pain,
weight loss, or fever were not noted. He was a current
smoker, having smoked 20 cigarettes a day for 15 years.
Computed tomography imaging of the chest revealed a 65 
50 mm mass in the middle mediastinum (Figure 1A). Serum
laboratory data were within normal limits. A bronchoscopic
examination revealed a compression against the outside of the
trachea. No other organs appeared to be affected on extensive
examination. Subsequent evaluation for serum tumor markers
revealed an increased level of AFP. Other examined markers,
including -human chorionic gonadotropin, carcinoembry-
onic antigen, and CA19-9, were within normal limits. Tho-
racoscopic examination revealed that the tumor was not
invading into the adjacent lung. On the basis of these find-
ings, we considered the tumor to have originated from the
middle mediastinum. A biopsy revealed poorly differentiated
carcinoma with neuroendocrine features. Thymic neuroendo-
crine carcinoma is exclusively located in the anterior-superior
mediastinum.1 Given the tumor’s location, the increase in the
serum concentration of AFP, and the patient’s young age, the
diagnosis of embryonal carcinoma was initially favored over
purely neuroendocrine neoplasm. The patient received neo-
adjuvant chemotherapy with bleomycin (30 mg/body) on
days 2, 9, and 16, etoposide (100 mg/m2) on days 1 to 5, and
cisplatin (20 mg/m2) on days 1 to 5. Treatment cycles were
repeated every 21 days for 4 cycles. The serum AFP level had
decreased to within normal limits in association with shrink-
age of the tumor by the end of the third cycle of chemother-
apy (Figure 1B, E). However, the AFP concentration started
to increase thereafter, and progression of the tumor was
confirmed after the fourth cycle of chemotherapy (Figure 1C,
E). The patient then received second-line chemotherapy with
cisplatin (80 mg/m2) on day 1 and paclitaxel (200 mg/m2) on
day 1 every 21 days for three cycles before surgery. The
serum AFP level again decreased in association with tumor
shrinkage (Figure 1D, E). Eight months after initial detection
of the tumor, the patient underwent a tumorectomy combined
with right upper lobectomy and tracheoplasty, given that the
tumor was found to invade the adjacent right upper lobe and
trachea at the time of surgery. Histopathologic examination
of the surgical specimen revealed a solid tumor nest with
massive necrosis. The tumor was relatively homogeneous
throughout the resection, showing sheets of cells with a high
nucleus-to-cytoplasm ratio. High-power magnification of the
tumor revealed that the tumor cells manifested marked neu-
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roendocrine features, such as frequent rosette structures and
trabecular arrangements, nuclear moldings, and prominent
mitoses (Figure 2A, B). The tumor cells also had abundant
nucleoli. Immunohistochemical analysis showed the tumor
cells to be diffusely positive for CK7 and neuroendocrine
markers including CD56, chromogranin A (Figure 2C), and
synaptophysin as well as negative for CD5, CD30, human
chorionic gonadotropin, placental alkaline phosphatase, he-
patocyte antigen, and thyroid transcription factor-1. No re-
gions of the specimen showed features of a germ cell tumor
or hepatoid carcinoma. On the basis of the morphology and
staining characteristics of the tumor, a pathologic diagnosis
of LCNEC was made. A small number of tumor cells showed
subtle but unequivocal positive staining for AFP (Figure 2D).
Thoracic radiotherapy was not able to be given because the
patient suffered from thoracic empyema after surgery. De-
spite intensive chemotherapy, he died of extensive recurrence
of carcinoma 4 months after the surgery.
FIGURE 1. Chest computed
tomography (CT) findings and
serum AFP levels in the patient.
A–D, Chest CT findings. A mass
in the middle mediastinum was
initially detected (A). The tumor
had shrunk after three cycles of
neoadjuvant chemotherapy (B),
but its progression had resumed
after the fourth cycle (C). The
tumor shrank again in response
to second-line chemotherapy
(D). E, Time course of the serum
concentration of AFP. The AFP
level was initially increased, it
decreased to within normal lim-
its (dotted line) in association
with tumor shrinkage during
first-line chemotherapy, but it
started to increase again after
the third cycle. The serum AFP
level again decreased in associa-
tion with tumor shrinkage dur-
ing second-line chemotherapy.
FIGURE 2. Histology and immunohistochem-
ical analysis of the tumor specimen obtained at
surgery. A, Hematoxylin-eosin staining revealed
solid tumor nests with areas of necrosis (arrow
heads). Note the homogeneous appearance of
the tumor. B, High-power magnification of the
tumor stained as in (A), showing numerous
rosettes (asterisk), abundant cytoplasm, chro-
matin clearing with occasionally prominent nu-
cleoli, nuclear molding (arrows), and frequent
mitosis (arrow heads). C, Immunohistochemical
staining for chromogranin A revealed diffuse
and intense cytoplasmic staining. D, Immuno-
histochemical staining for AFP, showing a focus
of tumor cells positive for AFP (arrows). Scale
bars: 1 mm, 50 .
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DISCUSSION
LCNEC is a relatively new category of pulmonary
neuroendocrine tumor, with affected individuals reported to
have a prognosis intermediate between those with atypical
carcinoid lung cancer and those with small cell lung cancer.10
Recent clinical studies indicate a 5-year survival rate of 27 to
67% even if patients are at pathologic stage I.2–4 Since its
original detection in the lung, LCNEC has been found in a
variety of extrapulmonary locations including gastrointestinal
sites and the uterine cervix.5–7 The present case was identified
as LCNEC originating in the mediastinum. Given the age of
the patient and the tumor location, a diagnosis of embryonal
carcinoma was initially considered, but no morphologic or
immunohistochemical features indicative of embryonal car-
cinoma were found on extensive pathologic analysis of the
surgical specimen. Primary mediastinal LCNEC is an ex-
tremely rare disorder and has been described in only a few
case reports to date.8–9
In the present case, the increased serum AFP level
decreased in association with tumor shrinkage in response to
chemotherapy, and the tumor was confirmed immunohisto-
chemically to produce AFP. AFP is the main component of
fetal serum in mammals. It is synthesized by visceral
endoderm of the yolk sac and fetal liver, but expression of the
AFP gene is greatly reduced at the time of birth. AFP-
producing carcinoma has been recognized for decades and
reported in various locations including the lung and medias-
tinum.11 In contrast to the present case, however, most can-
cers that produce AFP show morphologic features similar to
hepatocellular carcinoma. With regard to neuroendocrine
tumors, some case reports indicate that small cell carcinoma
can also produce AFP.12,13 As far as we are aware, however,
the present case is the first reported example of LCNEC
producing AFP. Given that the concept of LCNEC is rela-
tively new, this may not be that surprising, and previous
reports of small cell carcinoma may actually have been
diagnosed as LCNEC today. Our case raises the possibility
that the origin of mediastinal neuroendocrine tumors includ-
ing LCNEC may be mediastinal primordial germ cells. Ex-
amination of germ cell tumor markers in neuroendocrine
tumors may shed light on this matter.
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